Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Anforth

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
The British Journal of Dermatology|November 3, 2015
Treatment-specific utility weightings are needed for cost-utility analysis in metastatic melanomaD F Sebaratnam, R Anforth, P Fernández-Peñas
Clinical and Experimental Dermatology|April 16, 2013
Non-evolving linear facial plaqueA Mohd Affandi, R Anforth, S Chou, et al.
Actas Dermo-Sifiliograficas|September 20, 2016
Cutaneous Adverse Events of New Anti-melanoma Therapies: Classification and ManagementS J E Hwang, R Anforth, G Carlos, et al.
The British Journal of Dermatology|July 22, 2014
Cutaneous adverse events in patients treated with BRAF inhibitor-based therapies for metastatic melanoma for longer than 52 weeksR Anforth, G Carlos, A Clements, et al.
Radiography (London, England : 1995)|October 8, 2018
Variation in the length and structure of reports written by reporting radiographers: A retrospective studyA S Manning-Stanley, L Bonnett, T Mellett, et al.
The British Journal of Dermatology|July 23, 2013
Systemic retinoids for the chemoprevention of cutaneous squamous cell carcinoma and verrucal keratosis in a cohort of patients on BRAF inhibitorsR Anforth, T C M P Blumetti, A Clements, et al.
European Cytokine Network|November 27, 1998
Biological activity and brain actions of recombinant rat interleukin-1alpha and interleukin-1betaH R Anforth, R M Bluthe, A Bristow, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
The British Journal of Dermatology|November 3, 2015
Treatment-specific utility weightings are needed for cost-utility analysis in metastatic melanomaD F Sebaratnam, R Anforth, P Fernández-Peñas
Clinical and Experimental Dermatology|April 16, 2013
Non-evolving linear facial plaqueA Mohd Affandi, R Anforth, S Chou, et al.
Actas Dermo-Sifiliograficas|September 20, 2016
Cutaneous Adverse Events of New Anti-melanoma Therapies: Classification and ManagementS J E Hwang, R Anforth, G Carlos, et al.
The British Journal of Dermatology|July 22, 2014
Cutaneous adverse events in patients treated with BRAF inhibitor-based therapies for metastatic melanoma for longer than 52 weeksR Anforth, G Carlos, A Clements, et al.
Radiography (London, England : 1995)|October 8, 2018
Variation in the length and structure of reports written by reporting radiographers: A retrospective studyA S Manning-Stanley, L Bonnett, T Mellett, et al.
The British Journal of Dermatology|July 23, 2013
Systemic retinoids for the chemoprevention of cutaneous squamous cell carcinoma and verrucal keratosis in a cohort of patients on BRAF inhibitorsR Anforth, T C M P Blumetti, A Clements, et al.
European Cytokine Network|November 27, 1998
Biological activity and brain actions of recombinant rat interleukin-1alpha and interleukin-1betaH R Anforth, R M Bluthe, A Bristow, et al.
Pageof 1